Back to search
FDAFDA · Food and drugs·Recall number D-139-2013

Temodar (temozolomide) Capsule, 20 mg per capsule, 5 capsules per package, For Oral Administration, Rx Only, Cytotoxic, NDC: 0085-1519-02, Schering Corporation, Kenilworth, New Jersey, 07033

Published February 6, 2013 · Recall initiated: December 12, 2012

Summary

FDA records drug Class II recall D-139-2013, published February 6, 2013 and initiated December 12, 2012. Recalling firm: Schering-Plough Products, LLC; Status: Terminated; Reported quantity: 17,169 Packages; Lot: Lot: 0NCW005, Exp 02/2013. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: The recall is being initiated due to an out-of-specification result in the degradation product testing detected during stability monitoring.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Schering-Plough Products, LLC
Distributor
Nationwide and Puerto Rico
Lot
Lot: 0NCW005, Exp 02/2013
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Temodar (temozolomide) Capsule, 20 mg per capsule, 5 capsules per package, For Oral Administration, Rx Only, Cytotoxic, NDC: 0085-1519-02, Schering Corporation, Kenilworth, New Jersey, 07033 recalled?

Yes. FDA published recall D-139-2013 on February 6, 2013. Reported hazard: Failed Impurities/Degradation Specifications: The recall is being initiated due to an out-of-specification result in the degradation product testing detected during stability monitoring.

What should I do if I have this product?

Voluntary: Firm initiated · Letter